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Abstract
Background: To evaluate the influence of heart disease on clinical characteristics, quality of life, use of health
resources, and costs of patients with COPD followed at primary care settings under common clinical practice
conditions.
Methods: Epidemiologic, observational, and descriptive study (EPIDEPOC study). Patients ≥ 40 years of age with
stable COPD attending primary care settings were included. Demographic, clinical characteristics, quality of life (SF-
12), seriousness of the disease, and treatment data were collected. Results were compared between patients with
or without associated heart disease.
Results: A total of 9,390 patients with COPD were examined of whom 1,770 (18.8%) had heart disease and 78%
were males. When comparing both patient groups, significant differences were found in the socio-demographic
characteristics, health profile, comorbidities, and severity of the airway obstruction, which was greater in patients
with heart disease. Differences were also found in both components of quality of life, physical and mental, with
lower scores among those patients with heart disease. Higher frequency of primary care and pneumologist visits,
emergency-room visits and number of hospital admissions were observed among patients with heart diseases. The
annual total cost per patient was significantly higher in patients with heart disease; 2,937 ± 2,957 vs. 1,749 ± 2,120,
p < 0.05. Variables that were showed to be independently associated to COPD in subjects with hearth conditions
were age, being inactive, ex-smokers, moderate physical exercise, body mass index, concomitant blood
hypertension, diabetes, anxiety, the SF-12 physical and mental components and per patient per year total cost.
Conclusion: Patients with COPD plus heart disease had greater disease severity and worse quality of life, used
more healthcare resources and were associated with greater costs compared to COPD patients without known
hearth disease.
Background
Chronic obstructive pulmonary disease (COPD) is a pro-
cess characterized by the presence of a chronic and
poorly reversible obstruction of the airflow, related to an
abnormal inflammatory reaction, primary against
tobacco smoke [1]. In spite of the multiples campaigns
against tobacco consumption conducted in recent years,
nowadays, COPD is still an important problem of public
health, with constantly increasing prevalence and
mortality rates. Thus, in Spain, for instance, a prevalence
of 9.1% has been described in subjects between 40 and
70 years of age [2], and in Latin America the prevalence
ranges between 7.8% in Mexico City and 19.7% in Mon-
tevideo [3]. Concerning mortality, COPD represents the
fourth cause of death, both, in Spain and worldwide [1].
Different studies have suggested that subjects with this
condition are at an increased risk of cardiovascular mor-
bidity and mortality, which cannot exclusively be attrib-
uted to the fact of sharing the habit of smoking as an
etiological factor [4-6]. In fact, it has been demonstrated
that an impaired pulmonary function constitutes a risk
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ing habit, as important as the total cholesterol level [7].
Furthermore, several studies have shown that a substan-
tial percentage of deaths among patients with mild
COPD are the result of cardiovascular complications [8];
and in a wide epidemiologic study, an increase of cardi-
ovascular mortality was observed, mainly in subjects
with COPD under 65 years of age [4]. In this sense, sys-
temic inflammation has been postulated to play a con-
current role in the pathogenesis and natural history of
both diseases [9]. Heart conditions have also been
related with smoking that could lead to systemic inflam-
mation, then causing both health diseases.
Despite these data, the importance of establishing a
correct diagnosis and scoring the seriousness of both
processes combination is frequently underestimated
[10]. In fact, limited information is available on the real
influence of the presence of heart disease in patients
with COPD, mainly in primary care clinical practice,
where the percentage of patients with mild or moderate
COPD is very high. Relative to this fact, some authors
have questioned whether the results of typical clinical
trials conducted in patients with COPD can be extrapo-
lated to “real life” patients [11].
The primary objective of this study was to evaluate the
influence of heart disease on clinical characteristics,
quality of life, use of healthcare resources, and calcula-
tion of related costs of patients with COPD attended at
primary care settings under common clinical practice
conditions.
Methods
Design and Study Population
This study was part of the EPIDEPOC study, a descrip-
tive, epidemiological, observational, and multicentric
project, conducted at primary care settings with the
objective of estimating the use of health resources, and
assesses the quality of life of patients with stable COPD
[12].
Patient recruitment and calculation of the sample size
corresponded to that conducted in the EPIDEPOC
study. For calculation of sample size, a cluster design
was used, considering 3 types of variables: health cen-
tres, physicians, and medical records. As the health cen-
tres were considered to be homogeneous and
representatives of the Spanish geographical population,
the medical record was chosen as the unit of study and
the prescriber as the cluster. A previous study in a large
cohort of 1,510 primary care patients found that the
average annual cost per patient varied widely, with an
estimated standard deviation of €3,407 [13]. Assuming a
precision of €90, 5,505 medical records needed to be
evaluated. If the effect of the cluster design is also taken
into account, i.e., the loss of efficacy from the use of
clusters, assuming a correlation of 0.3 and a cluster size
of 5, a total of 2,422 prescribers and 12,111 medical
records would be required. The subjects were consecu-
tively included by primary care physicians in all the
Spanish Autonomous Communities, with a distribution
proportional to the population in each Community. The
patients were recruited during a period of three months
(from January 1 to March 31, 2003).
Patients of both genders, over 40 years of age, and
with a diagnosis of COPD made at least 12 months
b e f o r es t u d yi n i t i a t i o nw e r ei n c l u d e d .T h ed i a g n o s i so f
COPD was made according to the Spanish Society of
Pneumology and Thoracic Surgery (SEPAR) criteria,
based on the evidence, from a forced spirometry, of a
forced expiratory volume during the first second (FEV1)
lower than 80% of the reference value, and a ratio FEV1/
forced vital capacity (FVC) lower than 0.7 after a
bronchodilator test. Depending on the FEV1value, the
seriousness of the disease was qualified into three levels:
mild (FEV1: 60-80% of the reference value), moderate
(FEV1: 40-59% of the reference value), and serious
(FEV1: under 40% of the reference value), in accordance
with the SEPAR Criteria [14].
Subjects with neurological or psychiatric diseases that
could hamper the assessments during the study were
excluded. Patients who had suffered an exacerbation of
COPD within the previous month were excluded as
well. The exacerbation was defined as the impairment of
the patient’s clinical status characterized by increased
expectoration, the presence of purulence in the sputum,
increase of baseline dyspnea, or any combination of
these symptoms [15].
The Ethics Committee of the Fundación Hospital
Alcorcón approved the study, and all patients gave their
oral consent to participate.
Patients’ Evaluation
Patients attended only one visit, and socio-demographic,
seriousness of the disease, and use of healthcare
resources within the 12 previous months data from all
patients were collected. Furthermore, associated comor-
bidities, including the presence or absence of heart dis-
ease, according to the ICD-9 diagnostic criteria, were
recorded. The ICD-9 codes that were used to define the
presence of heart disease were: 410-114 (ischemic heart
disease) and 420-429 (other forms of heart diseases).
Patients were divided in two groups (with heart disease
and with no heart disease) according to this criterion.
All patients were administered the SF-12 quality of life
questionnaire, an abbreviated version of the SF-36
health questionnaire that contains 12 items [16,17].
These 12 items explain more than 90% of the variance
of the physical and mental component scores of the SF-
36. From them two scores can be calculated, the
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summary, using a value of 50 with a standard deviation
of 10 as reference population. In this study, the general
Spanish adult population has been used as reference
[18]. The SF-12 is scored from 0 (worst possible health
quality of life) to 100 (best possible quality of life).
The use of health resources by patients was obtained
from data recorded in medical records and through
patients’ interviews, in which the consumption of health
resources within the 12 previous months was recorded.
The collected health resources included the following:
drugs, medical visits (including visits to emergency
departments), complementary tests, hospitalizations,
oxygentherapy, and other non-pharmacologic treatments
and vaccines received. To obtain indirect costs, the
“human capital” method was used. This method uses a
basic hypothesis on the equivalence between the value
of lost productivity and the associated salary for obtain-
ing of this production. This is the loss of one working
day implies a production loss equal to the salary the
patient would have received that day. Information on
employment and salaries was obtained from the Spanish
National Statistics Institute [19]. For the study, the
number of lost working days due to the disease within
the previous year was recorded.
Statistical aspects
SPSS 14.0 statistical pack for Windows was used for the
analysis of data. Categorical variables were described
through frequencies and percentages, and continue vari-
ables through means, standard deviations, and minimum
and maximum values. A Pearson c
2 test was used to ana-
lyze the relationship between qualitative variables. A Stu-
dent t test for independent measures was used to calculate
means differences between both groups. The results were
adjusted for age and gender through the direct method,
using the Spanish population in accordance with the year
2003 census as the reference population. Multivariate ana-
lysis using logistic regression was conducted to explore
the impact of chronic heart disease on COPD. P values <
0.05 were considered statistically significant.
Annual costs were estimated by multiplying the unit
cost of each resource (cost per treatment day for drugs,
depending on the dose received) by the number of
resources used within the 12 months previous to the
study visit, and were expressed in annual costs per
patient. Unit costs of drugs were obtained from the
Pharmaceutical Catalogue of the General Council of
Pharmacists’ Colleges of Spain, while costs of other
health resources were obtained from the information on
costs of different procedures supplied by the managers
o ft h eÁ r e a8d eM a d r i d ,H o s p i t a ld eA l c o r c ó n ,a n d
Hospital de Móstoles.
Results
A total of 10,711 patients with COPD were assessed.
Information regarding patient background on hearth
condition was collected in 9,390 subjects (87.6%). Among
these patients, 1,770 (18.8%) had a concomitant heart dis-
ease; with 78% of them being males. Table 1 shows the
socio-demographic characteristics of patients according
to the presence of heart disease. Regarding tobacco con-
sumption, the percentage of ex-smokers was higher
among patients with heart disease (66.5%), compared to
those patients without this comorbidity (56.1%), while
the percentage of active smokers was significantly lower
(11.6% versus 20.7%, p < 0.05). In general, differences
were found between both patient groups in the practice
of physical exercise, level of obesity, severity of the air-
flow obstruction, and comorbidities; in all cases differ-
ences were against patients with a past history of heart
disease (Table 2). On the other hand, quality of life
Table 1 Socio-demographic characteristics of patients with COPD examined in function of the presence or the absence
of associated heart disease
Parameter Patients without heart disease
(n = 7,620)
Patients with heart disease
(n = 1,770)
p
Age (mean ± SD) 65.92 ± 9.56 73.73 ± 8.29 < 0.05
Gender: Male (%) 75.0 78.9 < 0.05
Labour status: < 0.05
Inactive (%) 73.5 93.4
Active (%) 26.5 6.6
Level of education:
No education (%) 19.4 26.7 < 0.05
Primary (%) 56.9 55.7
Secondary (%) 18.2 13.4
University (%) 5.6 4.1
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patients with associated heart disease in both SF-12 sum-
mary components, but particularly in the physical com-
ponent; 30.7 ± 8.7 vs. 37.0 ± 9.8, p < 0.05 (Table 2).
Among subjects with heart disease, a greater con-
sumption of anticholinergic drugs (88.6% vs. 83.9%, p <
0.05), as well as teophyllines (15.6% vs. 11.3%, p < 0.05),
and steroids, both inhaled (28.5% vs. 21.5%, p < 0.05)
and oral (7.4% vs. 5.3%, p < 0.05) was observed. Conver-
sely, no significant differences in the use of b2-adrener-
gic agonists or mucolytic drugs were found. Concerning
the past history of vaccinations, patients with heart dis-
ease had been more frequently submitted to anti-influ-
enza vaccination within the last campaign or anti-
pneumococcal vaccination at any time (Table 3).
Patients with heart disease had consumed significantly
more resources than those with no COPD-associated
heart disease. Therefore, mean numbers of primary care
and pneumology consultations, visits to emergency
departments, hospitalizations, and duration of hospital
admissions were significantly greater in the first patient
subgroup (Table 4). Due to the resulting cost, the pro-
longed length of hospital stay of patients with heart disease
should be highlighted; 11.82 ± 14.99 vs. 6.09 ± 10.32 (p <
0.05, Table 4).
Table 5 shows the costs of COPD by presence of an
associated heart disease. The annual total cost per
patient was significantly higher among patients with
heart disease than those without the condition; 2,937.19
± 2,956.69 vs. 1,749.25 ± 2,120.28, p < 0.05. This
increased total cost was due to significantly higher costs
in all cost components, included indirect costs; however,
due patients’ age, and to the fact of most patients were
retired, indirect costs had a limited impact. Due to the
increased length of hospital stay, the most expensive
component, differences in this component had the
greatest magnitude as well; 1,494.44 ± 2,321.38 vs.
658.13 ± 1,610.29 (p < 0.05, Table 5).
Table 2 Health profile, severity of the airflow obstruction according to the VEF1, comorbidities and quality of life
according to the SF12 of patients with COPD examined in function of the presence or the absence of associated heart
disease*.
Parameter Patients without heart disease
(n = 7,620)
Patients with heart disease
(n = 1,770)
p
Tobacco consumption:
Never (%) 23.3 21.9 < 0.05
Ex-smoker (%) 56.1 66.5
Active smoker (%) 20.7 11.6
Physical exercise:
None (%) 30.4 40.7 < 0.05
Light (%) 64.7 57.3
Moderate (%) 5.0 2.0
Level of obesity**:
Normal weight (%) 24.6 21.2 < 0.05
Overweight (%) 55.3 48.7
Obesity (%) 20.1 30.2
Severity of obstruction (VEF1):
Mild 37.7 24.4 < 0.05
Moderate 53.3 53.3
Serious 8.9 22.3
Comorbidities:
Blood hypertension (%) 40.8 64.3 < 0.05
Hypercholesterolemia (%) 37.7 44.5 < 0.05
Diabetes (%) 12.2 29.5 < 0.05
Gastroduodenal ulcer (%) 13.7 19.2 < 0.05
Depression (%) 10.9 16.3 < 0.05
Anxiety (%) 19.8 25.9 < 0.05
Quality of life (SF-12):
Mental component (mean ± SD) 48.7 ± 10.8 46.5 ± 11.9 < 0.05
Physical component (mean ± SD) 37.0 ± 9.8 30.7 ± 8.7 < 0.05
* All percentages and means have been adjusted to age and gender using the direct method.
** Normal weight (BMI < 27), overweight (BMI ≥ 27 and < 30), and obesity (BMI ≥ 30). NS: not significant. SF-12 range: 0 (worst possible quality of life) - 100
(best quality of life).
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tic regression, were showed to be independently asso-
ciated to COPD in subjects with hearth conditions were
age, being inactive, ex-smokers, moderate physical exer-
cise, body mass index, concomitant blood hypertension,
diabetes, anxiety, the SF-12 physical and mental compo-
nents and per patient per year total cost (table 6).
Discussion
T h ep r e s e n c eo fc o m o r b i d i t i e si sf r e q u e n ta m o n g
patients with COPD, although different studies have
shown a wide range of prevalence rates [1,20-23], possi-
bly due to differences in patient selection criteria and
severity of the disease among different studies. In our
study, we found a prevalence of hearth disease of 18.8%.
Unfortunately, the presence of both conditions is dread-
ful, and, as demonstrated in this study, significantly con-
tributes to the worse quality of life, and increased
resources consumption and costs of patients with
COPD.
The causal relationship between COPD and heart dis-
ease has been traditionally attributed to cigarette con-
sumption, but the exact mechanism has been broadly
studied recently [24]. Several epidemiologic studies have
indicated the importance of systemic inflammation in
the pathogenesis of arteriosclerosis and cardiovascular
events, and recent studies have suggested that COPD
patients have a prominent systemic inflammatory
response [25-30]. For instance, in patients with COPD
an increased C reactive protein (PCR) level, a known
marker of systemic inflammation, has been detected
[31-34]. Since an increased CRP is a risk factor for car-
diovascular diseases [35], the pathogenesis of both pro-
cesses may possibly start with an increased systemic
inflammation.
After recognizing the connection between pulmonary
and heart diseases, both conditions related from a
pathophysiologic point of view, it is important to deter-
mine the characteristics of patients with COPD and an
associated heart disease as a comorbidity. In this study
we observed that these patients, compared to those with
COPD but no associated heart disease, require more
respiratory drugs, have a worse quality of life, consume
more resources, and generate greater expenses.
Patients with COPD consume medicines stimulating
their cardiovascular system, as are sympathomimetic
drugs. These pharmacological agents may result in
increased blood pressure and cardiac frequency,
abnormalities that might lead to the development of a
cardiovascular event. The stimulation of the cardiovas-
cular system, might also lead to the occurrence of an
arrhythmia, some of them potentially life-threatenning
[4]. In this sense, in a recent metanalysis Salpenter et al
[36] evidenced an increased incidence of tachycardia
Table 3 Present drug treatment and vaccines of patients with COPD examined in function of the presence or the
absence of associated heart disease
Treatment Patients without heart disease
(n = 7,620)
Patients with heart disease
(n = 1,770)
p
Short-action b2-adrenergic agonists (%) 39.3 42.3 NS
Long-action b2-adrenergic agonists (%) 9.2 10.4 NS
Anticholinergic drugs (%) 83.9 88.6 < 0.05
Teophylline (%) 11.3 15.6 < 0.05
Inhaled steroids (%) 21.5 28.5 < 0.05
Oral steroids (%) 5.3 7.4 < 0.05
Mucolytic drugs (%) 8.5 10.2 NS
Antiinfuenza vaccine during the previous campaign (%) 86.7 91.0 < 0.05
Antipneumococcal vaccine at any time (%) 31.6 39.2 < 0.05
* All percentages and means have been adjusted to age and gender using the direct method.
NS: not significant.
Table 4 Use of health resources during the previous year in patients with COPD in function of the presence or the
absence of associated heart disease*.
Health resources Patients without heart disease
(n = 7,620)
Patients with heart disease
(n = 1,770)
p
No. of visits to the primary care doctor 6.48 ± 5.51 7.75 ± 6.59 < 0.05
No. of visits to the pneumology clinics 1.36 ± 1.40 1.79 ± 2.01 < 0.05
No. of visits to emergency departments 1.83 ± 0.83 2.10 ± 0.94 < 0.05
No. of hospital admissions 0.40 ± 1.10 0.90 ± 1.50 < 0.05
Length of hospital stay (days) 6.09 ± 10.32 11.82 ± 14.99 < 0.05
* Values are expressed as mean ± Standard deviation. All means have been adjusted to age and gender using the direct method. NS: not significant.
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b2-adrenergic agonists. This suggests that these abnorm-
alities might contribute to the increased number of car-
diovascular deaths among these patients. However, these
results have not been confirmed in later studies. There-
fore, in the TORCH study (TOwards a Revolution in
COPD Health), in which over 6,000 patients with COPD
were randomized to receive salmeterol, a salmeterol-flu-
ticasone combination, or placebo, no increases of overall
mortality or cardiovascular adverse events were shown
in the salmeterol group compared to the other groups
[37]. In our study, no differences have been found in the
use of b2-adrenergic agonists among patients with
COPD, regardless of the presence or the absence of
heart disease; however, an increased use of anticholiner-
gic drugs, bronchodilator drugs with lover cardiovascu-
lar effects, was observed among patients with heart
disease. Another drug class that might contribute to the
occurrence of tachyarrhythmia, even in the absence of
treatments increasing potassium levels, is the methyl-
xantines drug class [38]. However, in our study, patients
with heart disease were taking this type of bronchodila-
tors more frequently, possibly due to a greater severity
of COPD compared to patients with no associated heart
disease. The same was observed for the use of steroids,
in spite of previous studies demonstrating a relationship
between the use of oral steroids and the development of
auricular fibrillation and ventricular arrhythmia [38,39].
Relative to associated diseases, the presence of comor-
bidities constitutes an important factor determining the
quality of life of patients with COPD, regardless the
LVEF [40,41], and the use of health resources [42].
However, the specific influence of heart disease on the
quality of life of patients with COPD attending primary
care settings had not been assessed in previous studies.
Our study indicated worse scores in both components,
physical and mental, of quality of life questionnaire
among patients with COPD and associated heart disease.
On the other hand, comorbidities are factors predict-
ing an increased use of health resources [43]. In particu-
lar, the presence of a cardiovascular disease has
demonstrated to be an important cause of hospitaliza-
tion among patients with COPD [6]. In addition, this
study demonstrated greater lengths of hospital stay
among patients with COPD and associated heart disease,
compared to those patients with no cardiac comorbidity.
Increased numbers of primary care, pneumologist, and
emergency department visits was evidenced as well for
the first patient group. These results contrast with those
obtained in another recent study conducted in the UK,
demonstrating a negative correlation between the pre-
sence of comorbidity and the number of visits to pri-
mary care settings [44]. Nevertheless, the correlation
with the use of the second level of care was positive;
this suggesting that patients with a more serious disease
might have a closer link to this domain.
Comorbidities are factors predicting increased costs of
COPD, even more than parameters of pulmonary func-
tion. However, limited studies are available assessing the
financial impact of comorbidities management in COPD
patients. Our study, evidenced a significant increase of
direct costs among patients with COPD and associated
h e a r td i s e a s e ,c o m p a r e dt op atients with no associated
heart disease. Furthermore, the presence of heart disease
has demonstrated to be an independent factor determin-
ing the cost of COPD [45]. In contrast, a recent study
conducted in Spain, which obtained a similar prevalence
of cardiovascular diseases, could not demonstrate an
increase of overall costs of COPD as a consequence of
this comorbidity [46].
Table 5 Annual costs per patient of health resources used in patients with COPD in function of the presence or the
absence of associated heart disease.
Cost component (€) Patients without heart disease
(n = 7,620)
Patients with heart disease
(n = 1,770)
p
Visits to PC doctor 104.63 ± 93.01 124.37 ± 111.22 < 0.05
Visits to specialist doctor 88.87 ± 98.51 119.42 ± 140.80 < 0.05
Visits to the emergency department 127.00 ± 188.77 184.18 ± 229.74 < 0.05
Hospitalization 658.13 ± 1610.29 1494.44 ± 2321.38 < 0.05
Diagnostic tests 122.62 ± 135.92 164.78 ± 194.29 < 0.05
Drugs 483.57 ± 406.76 575.71 ± 441.79 < 0.05
Oxygentherapy 70.66 ± 258.76 215.53 ± 420.49 < 0.05
Vaccination
influenza 0.22 ± 0.60 0.14 ± 0.49 < 0.05
Pneumococcal 4.50 ± 6.77 5.62 ± 7.14 < 0.05
Sick leave days 76.61 ± 297.42 38.33 ± 281.31 < 0.05
Total cost 1,749.25 ± 2,120.28 2,937.19 ± 2,956.69 < 0.05
* All means have been adjusted to age and gender using the direct method. PC = Primary care.
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that force to be cautious when generalizing the results,
as the study design, possible inconsistencies among par-
ticipant professionals, and coordination between assis-
tance levels, obstructing the measurement of cost-
efficient actions. The two-stage sampling may be a lim-
itation, since the first selection of primary care physi-
cians was followed by a systematic patient’ss e l e c t i o n
through a procedure that might entail biases. The parti-
cipation of physicians was voluntary, which could mean
that these professionals were particularly interested in
this disease, and that this would have an effect on the
follow-up of the study patients. The high rate of partici-
pating physicians might have reduced the magnitude of
this bias, should it exist. Biases might also be present in
subjects’ selection. It should be taken into account that
not all COPD patients are treated in primary care cen-
t r e s ,o re v e ni nt h ep u b l i ch e alth care setting. In this
sense, those patients with more comorbidities (including
heart disease) are more likely of being treated in the
specialized care setting. Similarities between socio-
demographic characteristics of our patients and those of
other Spanish-based COPD studies are in favour of the
representative nature of the sample [2,47,48]. Finally, we
computed indirect costs in working population as well.
In this study, the inability to perform daily activities as a
consequence of the disease in retired subjects was not
considered a cost.
Further limitations to be taken into a count refer to
recall bias of data collection. Retrospective data collec-
tion of resource use is known to have this type of bias
problems. Moreover, primary care clinical records are
also known to be a substandard source, as a lot of the
resources are not written down in the patient chart. On
the other hand, higher prevalence of comorbidities may
also mean that COPD patients with heart disease are
more closely monitored (workup bias) so has more
diagnosis.
Conclusion
In conclusion, this study has shown that patient with
COPD and a heart disease as a comorbidity shows
worse quality of life, higher healthcare resources use,
increased consumption of drugs, and more disease man-
agement costs. Nevertheless, and due to the fact that
this was a cross sectional study, a cause-effect associa-
tion can not be established but a possible association
only which was the poorer outcomes with concurrent
heart disease. However, while patients with heart disease
were more likely to have other health factors playing a
role, poorer outcomes could certainly not to be the
cause. Additional studies providing new data on the
pathogenesis and management of patients with both
conditions are needed, with the purpose of trying to
improve quality of life as well as survival of patients
with COPD.
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Table 6 Variables independently associated to COPD
among chronic heart disease patients using multivariate
logistic regression analysis.
OR IC 95%
Age 1.06 (1.05-1.07)
Labour status:
Active 1 -
Inactive 1.57 (1.43-1.75)
Tobacco consumption:
Never 1 -
Ex-smoker 1.47 (1.22-1.76)
Active smoker 1.16 (0.89-1.50)
Physical exercise:
None 1 -
Light 1.10 (0.94-1.29)
Moderate 1.72 (1.03-2.87)
Level of obesity:
Normal weight 1 -
Overweight 1.04 (0.86-1.26)
Obesity 1.46 (1.18-1.81)
Comorbidities:
Blood hypertension 1.85 (1.59-2.15)
Diabetes 169 (1.42-2.01)
Anxiety 1.23 (1.03-1.48)
Quality of life (SF-12):
Mental component 0.99 (0.98-0.99)
Physical component 0.96 (0.95-0.96)
Annual total cost per patient 1.01 (1.01-1.02)
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